Lorazepam

Lorazepam for Anxiety Disorders | Lorazepam for sale

Indicated for management of anxiety disorders or for the short-term relief of symptoms of anxiety or anxiety associated with depressive symptoms

Anxiety or tension associated with stress of everyday life usually does not require treatment with an anxiolytic

Efficacy in long-term use (ie, >4 months), has not been assessed by systematic clinical studies

Tablets

• Initial: 2-3 mg PO q8-12hr PRN; not to exceed 10 mg/day
• Maintenance: 2-6 mg/day PO divided q8-12hr

Extended-release capsules (Loreev XR)

• Indicated for anxiety disorders in adults who are receiving stable, evenly divided, TID dosing with lorazepam tablets
• Recommended dose: Administer capsule PO qAM; dose equals the total daily dose of previously administered lorazepam tablets
• Dosage adjustment: Discontinue Loreev XR and switch to lorazepam tablets to adjust dosage

Short-Term Treatment of Insomnia

Tablets: 2-4 mg PO qHS

Preoperative Sedation, Anxiety Relief, & Anterograde Amnesia

0.05 mg/kg IM for 1 dose; 2 hours before surgery; not to exceed 4 mg (2 mg/dose in elderly), OR  

0.044 mg/kg IV for 1 dose; 15-20 minutes before surgery; not to exceed 4 mg (2 mg/dose in elderly)

Status Epilepticus

Usual 4 mg/dose slow IV at 2 mg/min

If seizure persists after 5-10 min, administer 4 mg IV again

Anxiolytic/Sedation in ICU (Off-label)

Intubated and mechanically ventilated patients

• 0.02-0.04 mg/kg loading dose IV
• 0.02-0.06 mg/kg intermittent IV q2-6hr PRN, OR  
• 0.01-0.1 mg/kg/hr continuous IV; not to exceed 10 mg/hr

Chemotherapy-Induced Nausea/Vomiting (Off-label)

0.5-2 mg PO/IV q6hr; PRN thereaft

Chronic Insomnia (Off-label)

2-4 mg PO qHS

Dosing Modifications

Renal impairment

• PO: Dose adjustment not necessary
• IV/IM: Use with caution in mild-to-moderate impairment; not recommended in severe impairment or renal failure
• IV/IM (prolonged periods or high doses): Monitor; risk of propylene glycol toxicity

Hepatic impairment

• PO: No dose adjustment recommended in mild-to-moderate impairment; use with caution (may require lower dose) in severe impairment
• IV/IM: Use with caution in mild-to-moderate impairment; not recommended in severe impairment of hepatic failure

Dosing Considerations

Periodically reassess the usefulness for individual patients

IV: Monitor respirations q5-15min and before each repeated IV dose